The MENTOR study is poised to change first-line-treatment recommendations for idiopathic membranous nephropathy.
Provenge is a breatkthrough treatment option for men with asymptomatic or minimally symptomatic metastatic, hormone-resistant PCa.
The scar tissue that forms on sections of some glomeruli in FSGS will lead to kidney failure if left untreated.
Ringing in the new year was especially exciting this time around for Ashutosh K. Tewari, MB, BS, head of the new Center for Prostate Cancer at New York-Presbyterian.
The incidence of AKI requiring dialysis is now higher than the incidence of ESRD requiring dialysis or transplant.
A promising hybrid device that works from the inside to provide renal functions beyond dialysis 24 hours a day, seven days a week, has the potential to change a lot of lives.
Considering that bone loss is a known side effect of ADT for men with PCa, it might seem logical that calcium and vitamin D supplementation would help manage this consequence.
Focusing on nephrology patients who become pregnant may seem to be a niche business, but as specialist Madeleine Pahl, MD, tells Renal & Urology News, this population is increasing.
Robert K. Nam, MD, MSc, and colleagues helped to shed light on the impact of UI in men who have undergone RP by studying rates of UI-corrective surgery.
Nephrologist and study coauthor Yoshio Hall, MD, discusses his team's findings with Renal & Urology News.
Dr. Clayman continues to make his mark as one of only two urologists in the nation to become a medical school dean.
Nobody had to ask Oliver Khakmahd, MD, twice to implement an EHR system in his large, busy nephrology practice.
Several new drugs have become available for treating advanced prostate cancer in the past year and a half.
When using ESAs to correct anemia in patients with chronic kidney disease, focus less on hitting a given hemoglobin target.
Having performed more than 1,200 brachytherapy treatments, Michael F. Sarosdy, MD, is convinced that this is a far better choice than surgery.